Compare MLYS & TENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLYS | TENB |
|---|---|---|
| Founded | 2019 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2023 | 2018 |
| Metric | MLYS | TENB |
|---|---|---|
| Price | $30.36 | $21.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 18 |
| Target Price | ★ $48.67 | $31.69 |
| AVG Volume (30 Days) | 998.0K | ★ 3.5M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.43 | 3.23 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $999,405,000.00 |
| Revenue This Year | N/A | $9.37 |
| Revenue Next Year | N/A | $7.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.04 |
| 52 Week Low | $12.59 | $15.73 |
| 52 Week High | $47.65 | $35.69 |
| Indicator | MLYS | TENB |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 60.21 |
| Support Level | $26.85 | $19.15 |
| Resistance Level | $31.19 | $21.25 |
| Average True Range (ATR) | 1.59 | 1.13 |
| MACD | 0.18 | 0.19 |
| Stochastic Oscillator | 84.81 | 65.54 |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.